A New Zealand-born biochemist who studied innate immune signaling, he pitched a new company idea to investor Mikael Blomqvist and co-founded Anocca in Sweden in 2014 as scientific founder and CEO to engineer TCR-T cell therapies for hard-to-treat cancers.